B Cell Lymphoma
From the Journals
The group’s new study evaluation tool, the ESMO-MCBS:H, is aimed at helping doctors and others determine the benefit of new blood cancer therapies...
Only a small percentage of eligible patients participate in clinical trials in the first place, and very few come from racial and ethnic minority...
Information from germline genetic testing could affect a patient’s cancer care.
Only 2%-3% of practicing oncologists are Black or Hispanic/Latino, says Yale Cancer Center doctor.
On Nov. 22, three FDA inspectors arrived at the sprawling Intas Pharmaceuticals plant south of Ahmedabad, India, and found hundreds of trash bags...
Progression-free survival benefit of 1 year with venetoclax-obinutuzumab is sustained long term in chronic lymphocytic leukemia, trial analysis...
Glofitamab, a T cell–engaging bispecific antibody, has been approved by the Food and Drug Administration for adults with DLBCL.
Investigators say axi-cel should become the standard of care for second-line large B-cell lymphoma.
Only 64% of centers said they are still able to continue treating all current patients receiving carboplatin.
Primary analysis of the TRANSCEND CLL 004 trial showed that a single dose of CAR T therapy achieved durable responses in CLL and SLL, with a...